Sanofi Partners with NBA Champion Karl-Anthony Towns to Promote COVID-19 Vaccination Awareness
Sanofi has launched a campaign with NBA player Karl-Anthony Towns to raise awareness about COVID-19 vaccination importance, particularly for at-risk individuals. The initiative highlights NUVAXOVID, an FDA-approved protein-based vaccine.
Pharmaceutical company Sanofi has partnered with NBA star Karl-Anthony Towns to increase awareness surrounding the importance of COVID-19 vaccination, especially during respiratory virus season. The campaign aims to leverage Towns' personal experiences with the virus to encourage eligible individuals, particularly those at higher risk, to discuss vaccination options with healthcare providers.
The initiative prominently features NUVAXOVID, the only protein-based, non-mRNA COVID-19 vaccine approved by the FDA. Sanofi highlights that this vaccine utilizes recombinant protein technology, a platform that has been employed in certain modern flu vaccines for years.
Karl-Anthony Towns, sharing his personal journey with COVID-19 and its impact on his family, emphasizes the significance of prioritizing health. He encourages informed conversations about available vaccines, stating that his experiences have shaped his perspective on health protection.
The campaign also seeks to inform the public about the ongoing risks associated with COVID-19 and the necessity of making prevention a health priority. Sanofi notes that understanding diverse vaccination options is crucial for improving vaccination rates. NUVAXOVID is indicated for individuals aged 65 and older, and those aged 12-64 with underlying conditions that increase their risk for severe COVID-19 outcomes.
Sanofi aims to support public health strategies by offering multiple vaccine choices, potentially addressing vaccine hesitancy. The company holds marketing authorization for NUVAXOVID in the U.S., EU, and UK, with plans to expand its availability to additional markets.